# 89Zr-labeled Pembrolizumab in Patients With Non-small-cell Lung Cancer

> **NCT03065764** · PHASE2 · UNKNOWN · sponsor: **Amsterdam UMC, location VUmc** · enrollment: 10 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** 89Zr-Pembrolizumab

## Key facts

- **NCT ID:** NCT03065764
- **Lead sponsor:** Amsterdam UMC, location VUmc
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-01-20
- **Primary completion:** 2019-12-01
- **Final completion:** 2019-12-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2017-08-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03065764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03065764, "89Zr-labeled Pembrolizumab in Patients With Non-small-cell Lung Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03065764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*